Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 6/20 | 0.38 |
| ▸ | PARP11 | Q9NR21 | 6/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31079201 | 0.95 | MAPK1 (0.47) | MAPK1CDK4CCND1CCND3CDK6 | |
| SCHEMBL29964066 | 0.91 | MAPK1 (0.45) | MAPK1CDK4CCND1CCND3CDK6 | |
| SCHEMBL29964642 | 0.91 | MAPK1 (0.45) | MAPK1CDK4CCND1CCND3CDK6 | |
| SCHEMBL29964622 | 0.91 | MAPK1 (0.49) | MAPK1CDK4CCND1CCND3CDK6 | |
| SCHEMBL31079344 | 0.90 | MAPK1 (0.44) | MAPK1CDK4CCND1CCND3CDK6 | |
| SCHEMBL31079045 | 0.90 | MAPK1 (0.42) | MAPK1PARP10PARP11GSK3BMAPKAPK2 | |
| SCHEMBL29964137 | 0.88 | MAPK1 (0.45) | MAPK1PARP10PARP11GSK3BMAPKAPK2 | |
| SCHEMBL29964192 | 0.85 | MAPK1 (0.44) | MAPK1CDK4CCND1CCND3CDK6 | |
| SCHEMBL24680933 | 0.85 | MAPK1 (0.55) | MAPK1CDK4CCND1CCND3CDK6 | |
| SCHEMBL29914601 | 0.85 | MAPK1 (0.55) | MAPK1CDK4CCND1CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | MAPK1 141/4885CDK4 258/4885CCND1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.